Travere Therapeutics Inc (NASDAQ: TVTX) on Friday, soared 7.49% from the previous trading day, before settling in for the closing price of $13.49. Within the past 52 weeks, TVTX’s price has moved between $5.12 and $25.29.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 13.83% over the last five years. The company achieved an average annual earnings per share of 69.14%. With a float of $87.44 million, this company’s outstanding shares have now reached $87.45 million.
The firm has a total of 385 workers. Let’s measure their productivity. In terms of profitability, gross margin is 92.24%, operating margin of -138.0%, and the pretax margin is -137.45%.
Travere Therapeutics Inc (TVTX) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Travere Therapeutics Inc is 1.50%, while institutional ownership is 109.19%. The most recent insider transaction that took place on Apr 11 ’25, was worth 631. Before that another transaction happened on Feb 12 ’25, when Company’s SENIOR VICE PRESIDENT, R&D sold 5,200 for $23.53, making the entire transaction worth $122,356. This insider now owns 98,519 shares in total.
Travere Therapeutics Inc (TVTX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 69.14% per share during the next fiscal year.
Travere Therapeutics Inc (NASDAQ: TVTX) Trading Performance Indicators
Travere Therapeutics Inc (TVTX) is currently performing well based on its current performance indicators. A quick ratio of 2.04 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.10, a number that is poised to hit -0.55 in the next quarter and is forecasted to reach 1.03 in one year’s time.
Technical Analysis of Travere Therapeutics Inc (TVTX)
Analysing the last 5-days average volume posted by the [Travere Therapeutics Inc, TVTX], we can find that recorded value of 2.35 million was better than the volume posted last year of 1.74 million. As of the previous 9 days, the stock’s Stochastic %D was 18.24%. Additionally, its Average True Range was 1.41.
During the past 100 days, Travere Therapeutics Inc’s (TVTX) raw stochastic average was set at 12.84%, which indicates a significant decrease from 18.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.13% in the past 14 days, which was higher than the 60.67% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.81, while its 200-day Moving Average is $15.90. Now, the first resistance to watch is $15.07. This is followed by the second major resistance level at $15.63. The third major resistance level sits at $16.60. If the price goes on to break the first support level at $13.54, it is likely to go to the next support level at $12.57. Should the price break the second support level, the third support level stands at $12.01.
Travere Therapeutics Inc (NASDAQ: TVTX) Key Stats
Market capitalization of the company is 1.29 billion based on 88,772K outstanding shares. Right now, sales total 233,180 K and income totals -321,550 K. The company made 74,790 K in profit during its latest quarter, and -60,260 K in sales during its previous quarter.
